The study, led by Hamed Nouri of Gonabad University of Medical Sciences together with colleagues from Shahid Beheshti and Gonabad Universities of Medical Sciences, set out to address one of the most persistent problems in institutional elder care. Older adults frequently move into nursing homes because of physical frailty, cognitive decline, or the absence of caregivers able to support them at home. Whatever the reason, the transition almost always involves a degree of separation from the family network that once structured daily life. That severing of ties, the researchers note, can quietly erode mental health, feeding loneliness, hopelessness, and the slow accumulation of depressive symptoms that often go undetected in busy institutional settings.

To test whether routine video calls could counteract this process, the team designed a quasi-experimental study conducted in 2022 across nursing homes in Tabriz, a major city in northwestern Iran. Using cluster sampling, they enrolled 61 older adults and randomly assigned them to two groups. Twenty-nine participants in the intervention group received weekly video calls with their family members for two months, delivered alongside the normal schedule of in-person visits. The remaining 32 participants in the control group continued with routine visits only, receiving no structured video communication. The design allowed the researchers to isolate the specific contribution of the video-call program from the baseline care environment that all residents shared.

The outcome measures were two of the most widely used instruments in geriatric research. Depression was assessed with the Geriatric Depression Scale, a validated screening tool designed specifically for older populations and, in its shortened 15-item form, efficient enough for repeated administration in clinical settings. Perceived social support was measured with the Multidimensional Scale of Perceived Social Support, or MSPSS, which captures how supported individuals feel across distinct domains, including family, friends, and significant others. Both instruments were administered at baseline and again after the two-month intervention period, and the data were analyzed in SPSS version 26 with statistical significance set at a p value below 0.05.

The results were striking in both magnitude and consistency. After two months, the mean depression score in the intervention group was significantly lower than in the control group, with an effect size of 0.87 and a p value of 0.001. In behavioral research, an effect size approaching 0.9 is considered large, suggesting that the video-call intervention produced a substantial difference rather than a marginal statistical blip. In practical terms, residents who spoke with their families on a screen each week reported meaningfully fewer depressive symptoms than those who relied on routine contact alone.

The intervention also reshaped how supported the residents felt. Perceived social support scores rose significantly in the video-call group relative to controls, with an effect size of 0.67 and a p value of 0.01. This is a moderate-to-large effect, and it points to a plausible psychological mechanism underlying the improvement in mood. Perceived social support, the subjective sense of being cared for and connected to others, is one of the best-established protective factors against depression across the lifespan. By giving residents a reliable, recurring channel of family contact, the intervention appears to have strengthened that psychological buffer, and the mood benefits followed.

The technical simplicity of the intervention is part of its appeal. Unlike complex telemedicine platforms that require specialized equipment, training, and ongoing technical support, the program relied on ordinary video calls, delivered weekly, with the residents’ own family members. The effect was measured over a short period of just two months, meaning the benefits emerged quickly. For nursing home administrators, this suggests that a video-communication program could be introduced with minimal infrastructure and at low cost, layered onto existing visiting arrangements rather than replacing them. The study’s authors conclude that video communication can be used in nursing homes to enhance the short-term well-being of residents.

As with any study, the design carries limitations worth keeping in view. The trial was quasi-experimental rather than a fully randomized controlled trial, which is why the authors report it was not registered in a clinical trials registry. Although participants were randomly assigned to the two groups, cluster sampling within nursing homes introduces the possibility of site-level differences that a larger, multi-center randomized design would better control. The sample of 61 participants is modest, and the two-month follow-up captures short-term effects only; whether the mood benefits persist, accumulate, or fade once the calls stop remains an open question. The findings were also drawn from a specific cultural context in Iran, where family ties and visiting norms may shape both the feasibility and the emotional weight of video contact, so replication in other settings will be important.

The ethical framework of the study was carefully documented. The research received approval from the Ethics Committee of Gonabad University of Medical Sciences under ethics code IR.GMU.REC.1401.039, and written informed consent was obtained from all participants, who were fully informed about the study’s objectives and the research team before taking part. The researchers also completed the necessary permissions and coordination with the directors and management of the nursing homes involved. The work received no specific grant from funding agencies in the public, commercial, or not-for-profit sectors, and the authors declare no competing interests.

For a rapidly aging world population, the implications extend well beyond Tabriz. Depression in later life is associated with worse physical health outcomes, higher rates of institutionalization, elevated health care costs, and increased mortality, yet it remains underdiagnosed and undertreated in care facilities. Interventions that are cheap, scalable, and acceptable to older adults are urgently needed. This study suggests that the humble video call, already woven into the daily lives of younger generations, may be one of the most accessible tools available. As families disperse across cities, countries, and continents, scheduled screens may become a standard prescription of modern elder care, bridging the distance that separates aging parents from the children and grandchildren who love them.

Subject of Research: Effect of family video calls on depression and perceived social support in nursing home residents

Article Title: Impact of family video calls on depression and perceived social support among older adults residing in nursing home residents in Tabriz

Article References: Nouri, H., Rajaee, M., BasiriMoghadam, M., & Sadeghmoghadam, L. (2026). Impact of family video calls on depression and perceived social support among older adults residing in nursing home residents in Tabriz. BMC Geriatrics. https://doi.org/10.1186/s12877-026-08282-0

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08282-0

Keywords: nursing homes, older adults, depression, social support, video calls, telemedicine, geriatrics, mental health, family communication, Iran, Impact, family

The synaptotagmin family consists of seventeen membrane-associated regulators in mammals, each characterized by a short N-terminal transmembrane region and two cytoplasmic C2 domains that bind calcium with widely varying affinities. This heterogeneity is central to the review’s framework. Only a subset of isoforms functions as conventional fast calcium sensors; several others possess atypical or incomplete calcium-binding sites and appear to perform roles that do not depend on calcium triggering at all, such as membrane trafficking control, receptor turnover, and stress-response signaling. The authors organize the family by function, distinguishing rapid-release sensors such as SYT1, SYT2, and SYT9 in defined neuronal populations, activity-dependent and astrocytic secretion mediated by SYT4, asynchronous release and synaptic dynamics governed by SYT7, and a broader group including SYT3, SYT10, SYT11, SYT13, and SYT17 that connects membrane dynamics to trafficking, proteostasis, and neuronal resilience.

SYT1 remains the archetype. Embedded in synaptic vesicle membranes, it clamps the SNARE fusion machinery until an action potential delivers a pulse of calcium into the presynaptic terminal, at which point its C2 domains insert into membrane phospholipids and drive fast synchronous release. Human mutations in SYT1 produce a severe neurodevelopmental syndrome marked by intellectual disability, hypotonia, and epileptic activity, illustrating how a single point of failure in the fusion apparatus can derail brain development as a whole. The review also highlights emerging translational evidence around SYT1: proteins released from damaged synapses can be detected in cerebrospinal fluid, and SYT1 has been proposed as a candidate biomarker of synaptic injury. The authors are careful to frame this as promising but not yet clinically validated, a distinction that matters in a field where biomarker enthusiasm frequently outpaces reproducibility.

Where SYT1 mediates the lightning-fast synchronous component of neurotransmission, SYT2 and SYT9 handle fast release in specific neuronal populations, including circuits of the neuromuscular junction and specialized sensory pathways. Defects in these isoforms link directly to congenital myasthenic syndromes and neuromuscular junction disease, where the reliability of transmitter release determines whether muscle fibers receive adequate activation. SYT7, by contrast, shapes asynchronous release and vesicle recycling kinetics, fine-tuning the temporal structure of synaptic signaling and supporting forms of synaptic plasticity that depend on residual calcium. SYT4 occupies yet another niche, regulating activity-dependent secretion not only in neurons but also in astrocytes, thereby coupling neuronal activity to glial signaling and to the release of factors such as brain-derived neurotrophic factor that consolidate long-term synaptic change.

The review’s most distinctive contribution may be its treatment of the less glamorous isoforms. SYT3, located predominantly on the presynaptic plasma membrane rather than on vesicles, participates in activity-dependent bulk endocytosis and in the retrieval of synaptic vesicle components after intense stimulation. The authors describe preclinical intervention evidence suggesting that modulating SYT3-dependent endocytosis can protect synapses under metabolic stress, positioning the protein as a candidate therapeutic node. SYT13 likewise emerges from preclinical studies as a neuroprotective factor, with experimental manipulation of its expression influencing neuronal survival pathways, although the authors emphasize that such findings remain at the bench rather than the bedside.

SYT11 occupies a particularly compelling position at the intersection of membrane trafficking and protein quality control. The review identifies SYT11 as a Parkinson’s disease-related trafficking and proteostasis node, connecting vesicular transport, lysosomal function, and the cellular stress responses that determine whether damaged proteins are cleared or accumulate. Given that lysosomal dysfunction and protein aggregation are central themes in Parkinson’s pathology, a synaptotagmin isoform that participates in lysosomal exocytosis and autophagic flux offers a mechanistic bridge between two research literatures that have historically run in parallel. SYT10, expressed notably in the suprachiasmatic nucleus and involved in neurotrophin trafficking, and SYT17, associated with palmitoylation-dependent membrane association and stress signaling, round out a picture of a family whose roles extend deep into the glial and homeostatic dimensions of nervous system biology.

Human genetics, the authors acknowledge, provides comparatively limited direct evidence for some of these connections. The clearest clinical signal involves SYT14, where human genetic data link the isoform to an ataxic phenotype, consistent with its expression in Purkinje cells and its role in spinocerebellar neurodegeneration. For many other family members, the disease associations rest on animal models, cellular studies, and correlative human data rather than definitive Mendelian mutations. The review is notable for its evidence-stratified approach: the authors explicitly separate fast-release sensors with robust genetic and biophysical support, trafficking and proteostasis isoforms supported largely by preclinical work, and biomarker candidates whose clinical utility remains unproven. This candor about the strength of evidence is itself a contribution, offering a roadmap for where the field most urgently needs validation.

Unifying these strands is the concept of neuronal vulnerability. The authors propose a cellular and molecular framework in which synaptotagmin dysfunction destabilizes four interlocking processes: precise membrane fusion, vesicular trafficking and receptor turnover, proteostasis, and stress-response signaling. Because neurons are post-mitotic and metabolically demanding, they tolerate disruption of these processes poorly. Calcium-permeable AMPA receptor insertion, calmodulin-dependent signaling, and the balance between long-term potentiation and synaptic depression all depend on the regulated exo-endocytic cycle that synaptotagmins help orchestrate. When that cycle falters, excitotoxic signaling rises, receptor remodeling goes awry, and the neuron’s capacity to buffer stress erodes, linking a molecular defect in vesicle biology to the slow attrition of neural circuits observed in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis.

The translational implications are carefully hedged but genuinely intriguing. Beyond the SYT1 cerebrospinal fluid biomarker candidate and the preclinical interventions targeting SYT3 and SYT13, the review raises the possibility of adeno-associated virus-based gene approaches and small-molecule modulation of calcium-dependent membrane insertion as future therapeutic strategies, while stressing that none has reached clinical validation. The authors also note the relevance of synaptic vesicle glycoprotein 2A, a target of existing antiepileptic drugs and a widely used PET imaging marker of synaptic density, as a benchmark for how synaptic proteins can become clinically actionable. Whether synaptotagmins will follow that path depends on filling the gaps between biophysical mechanism, animal disease models, and human cohorts.

What emerges from this synthesis is a portrait of the synaptotagmin family as a systems-level regulator of nervous system health rather than a collection of interchangeable calcium sensors. From the millisecond choreography of vesicle fusion to the years-long trajectory of neurodegeneration, these proteins occupy decision points where membrane dynamics meet cellular survival. As the authors conclude, synaptotagmin dysfunction links membrane dynamics, synaptic instability, receptor remodeling, and stress-response failure into a coherent pathway toward neuronal vulnerability. For researchers hunting the molecular roots of neurological disease, that framework reframes an old question, how neurons communicate, into an urgently contemporary one: how the same machinery that transmits the mind can, when it breaks, break the neuron itself.

Subject of Research: Synaptotagmin family proteins and their roles in synaptic vesicle fusion and neurological disorders

Article Title: Synaptotagmin family proteins in neurological disorders: from synaptic vesicle fusion to neuronal vulnerability

Article References: Cui, J., He, J., Su, K., Luo, X., Wang, Z., Song, F., & Zhang, M. (2026). Synaptotagmin family proteins in neurological disorders: from synaptic vesicle fusion to neuronal vulnerability. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06446-0

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06446-0

Keywords: synaptotagmin, synaptic vesicle fusion, C2 domains, SNARE complex, neurodegeneration, SYT1, Parkinson's disease, lysosomal exocytosis, synaptic plasticity, neurodevelopmental disorder, family, proteins

Lysine demethylases, often abbreviated KDMs, are enzymes that remove methyl chemical groups from lysine residues on histone proteins, the spools around which DNA is wound inside every cell. This seemingly simple act of demethylation has profound consequences for chromatin architecture and gene expression. When KDMs malfunction, the delicate epigenetic balance that governs which genes are switched on or off can be disrupted, contributing to uncontrolled cell proliferation, evasion of programmed cell death, and the development of metastatic behavior. In breast cancer specifically, individual members of this enzyme family have previously been implicated in tumor progression and therapeutic resistance, but a holistic, multi-database portrait of the entire family has been conspicuously lacking.

To construct that portrait, the research team led by investigators at Tabriz University of Medical Sciences harnessed an impressive arsenal of publicly available bioinformatics platforms. They drew upon UALCAN for tumor versus normal expression comparisons, bc-GenExMiner for clinicopathological correlations, the Kaplan-Meier Plotter for survival analyses, cBioPortal for genomic alteration profiling, STRING and Cytoscape for protein interaction network construction, Enrichr for pathway enrichment, MethSurv for CpG methylation survival analysis, GSCALite for drug sensitivity correlations, and TIMER for immune infiltration assessments. All gene names were standardized to HGNC-approved symbols to ensure consistency across the disparate data sources, a methodological safeguard that strengthens the reliability of cross-platform integration.

The analysis revealed that KDM genes do not behave uniformly across breast cancer. Instead, they display sharply divergent expression patterns depending on the molecular subtype of the tumor. Genes including KDM1A, KDM1B, KDM4C, KDM4D, KDM4E, and KDM5A were significantly upregulated in triple-negative and basal-like breast cancers, the most aggressive and hardest-to-treat subtypes, while genes such as KDM2B, KDM3B, KDM4B, KDM6A, and KDM6B were markedly downregulated in the same contexts. Pairwise co-expression analysis within the triple-negative cohort identified two distinct modules: an oncogenic cluster anchored by a strong correlation between KDM1B and KDM5A, and a separate suppressor module linking KDM3B with PHF2. This architecture suggests that groups of demethylases may act cooperatively, either fueling or restraining tumor aggressiveness, rather than functioning as isolated molecular actors.

Survival analysis delivered some of the study’s most clinically resonant findings. Higher expression of KDM1B, KDM4A, KDM4B, KDM5A, KDM5C, KDM6A, and RSBN1 was significantly associated with improved overall survival, with KDM5C showing one of the strongest protective effects. In stark contrast, elevated KDM5B expression predicted shorter overall survival and poorer relapse-free survival, marking it as a candidate adverse prognostic marker. Relapse-free survival analysis extended this picture further, implicating elevated KDM5A, KDM5B, and KDM7A in earlier relapse while confirming the protective associations of more than a dozen other family members. Taken together, these data suggest that a patient’s KDM expression signature could one day inform risk stratification and guide the intensity of adjuvant therapy.

Genomic alteration analysis through cBioPortal, drawing on more than one thousand invasive breast carcinoma samples, identified KDM5B as the most frequently altered KDM gene, with amplification emerging as the dominant mechanism of dysregulation in roughly eighteen percent of tumors. Crucially, alterations in KDM5B, KDM2A, and KDM4C were strongly enriched in metastatic disease, aggressive histologic subtypes including infiltrating ductal and metaplastic carcinomas, and hormone receptor-negative phenotypes. Many of these amplifications and missense mutations clustered within functional domains such as the JmjC catalytic core and DNA-binding regions, implying that the alterations are not passenger events but likely enhance demethylase activity in ways that actively promote tumor progression. Protein interaction network modeling pinpointed KDM6A, KDM6B, KDM1A, KDM1B, and PHF8 as the central regulatory hubs within the broader epigenetic landscape of breast cancer.

Perhaps the most therapeutically provocative dimension of the study involves drug sensitivity. Cross-referencing KDM expression with large pharmacogenomic datasets from the Genomics of Drug Sensitivity in Cancer and Cancer Therapeutics Response Portal revealed that most KDM genes correlate negatively with drug sensitivity, meaning their overexpression may actively foster chemotherapy resistance. KDM2B stood out as the linchpin, showing the strongest and most consistent correlations across both datasets. Elevated KDM2B expression was linked to reduced sensitivity to Methotrexate, Doxorubicin, PX-12, I-BET-762, and Belinostat, clinically relevant agents spanning antifolate, anthracycline, redox-targeting, bromodomain-inhibiting, and HDAC-inhibiting classes. Prior experimental work in glioblastoma and other models has shown that KDM2B inhibition impairs cancer stem-like cell survival by inducing DNA damage and apoptosis, providing a plausible mechanistic rationale for how targeting this enzyme could resensitize tumors to standard chemotherapy.

The study also uncovered a striking methylation dimension. Using MethSurv, the researchers identified dozens of individual CpG sites within KDM genes whose methylation status was significantly associated with patient survival, including thirty-five prognostically relevant CpG sites in KDM2B alone and forty-six in KDM4B. This epigenetic crosstalk between histone demethylase genes and their own DNA methylation patterns underscores the layered complexity of cancer epigenetics and hints at potential biomarker applications beyond simple mRNA measurement. Meanwhile, enrichment analysis confirmed that KDM family genes are centrally involved in histone lysine demethylation, chromatin remodeling, 2-oxoglutarate-dependent dioxygenase activity, and metabolic pathways, connecting these enzymes to the metabolic reprogramming that is increasingly recognized as a hallmark of malignancy.

Immune infiltration analysis through TIMER added yet another layer of significance. KDM5A, KDM6A, and KDM7A expression correlated strongly and positively with CD8-positive T cell infiltration, suggesting these demethylases may help shape anti-tumor immunity. KDM2B showed notable associations with dendritic cells, neutrophils, CD4-positive T cells, and B cells, while KDM6A correlated with macrophage presence. Given the central role of tumor immune microenvironment composition in determining response to immunotherapy, these correlations suggest that KDM expression profiles could eventually help predict which patients are most likely to benefit from immune checkpoint inhibitors. The authors are careful to acknowledge the principal limitation of their work: it is entirely computational, relying on public databases without wet-lab experimental validation. Future studies employing in vitro knockdown assays and in vivo models will be essential to confirm these associations and dissect the underlying molecular mechanisms. Nevertheless, by synthesizing expression, survival, mutation, methylation, drug sensitivity, and immune data into a single unified framework, this investigation delivers the most complete picture to date of how the lysine demethylase family operates in breast cancer, and it does so with a clarity that should accelerate the translation of epigenetic insights into genuinely personalized therapeutic strategies.

The biological significance of lysine demethylation stems from the fact that methylated lysine residues on histone tails can carry distinct methylation states — mono-, di-, or trimethyl — and each state conveys a different transcriptional message. The KDM family reflects this complexity, comprising two mechanistically distinct classes: the flavin adenine dinucleotide-dependent amine oxidases such as KDM1A and KDM1B, and the larger group of JmjC-domain proteins that require iron and 2-oxoglutarate as cofactors. This enzymatic split has practical consequences for drug discovery, since the two classes are inhibited through entirely different chemical strategies, and several small-molecule demethylase inhibitors are already being evaluated in early-phase clinical trials for hematologic and solid malignancies.

The subtype-specific expression patterns observed in this study align with a broader principle in breast cancer biology: epigenetic regulators frequently act in a context-dependent fashion, behaving as oncogenes in one molecular background and tumor suppressors in another. This duality helps explain why broad demethylase inhibition may not be a viable therapeutic strategy, and why a precision approach — one that profiles a patient’s tumor for specific KDM alterations before selecting an epigenetic drug — is likely to be more fruitful.

The strong correlations between KDM expression and immune cell infiltration also connect the family to the emerging field of epigenetic immunomodulation. Chromatin regulators are increasingly understood to control the expression of immune checkpoints, antigen presentation machinery, and cytokine signaling pathways, and combining epigenetic drugs with immune checkpoint blockade has become an active area of clinical investigation. The observed links between KDM5A, KDM6A, and CD8-positive T cell infiltration provide a computational foundation for testing such combinations in breast cancer settings.

It is worth noting that the study’s findings derive entirely from curated patient cohorts within platforms built on The Cancer Genome Atlas and related resources, and the reported effect sizes — such as the hazard ratio of 1.5 for KDM5B — represent statistical associations rather than demonstrated causation. Translating these computationally derived hypotheses into clinical utility will require laboratory validation and, ultimately, prospective testing of KDM-based biomarkers in independent patient populations.

Subject of Research: Integrated bioinformatics profiling of the lysine demethylase gene family in breast cancer

Article Title: Integrated bioinformatics profiling of the lysine demethylase gene family in breast cancer

Article References: Mirzaei, Z., Barati, T., Ebrahimi, A., & Khaniani, M. S. (2026). Integrated bioinformatics profiling of the lysine demethylase gene family in breast cancer. Discover Biotechnology, 3(1), Article 9. https://doi.org/10.1007/s44340-026-00055-0

Image Credits: AI Generated

DOI: 10.1007/s44340-026-00055-0

Keywords: Integrated, bioinformatics, profiling, lysine, demethylase, gene, family, breast, cancer, scientific research